Phase II Trial of Sorafenib in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck or Nasopharyngeal Carcinoma Conference Paper uri icon

  • Overview
  • Research
  • Identity
  • Additional Document Info
  • View All


  • PURPOSE: To determine the efficacy and safety of single-agent sorafenib in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN) and nasopharyngeal carcinoma (NPC). PATIENTS AND METHODS: In this single-arm phase II trial, oral continuous sorafenib was administered in 28-day cycles. Patients had


  • Elser, Christine
  • Siu, Lillian L
  • Winquist, Eric
  • Agulnik, Mark
  • Pond, Gregory
  • Chin, Soo F
  • Francis, Peggy
  • Cheiken, Robin
  • Elting, James
  • McNabola, Angela
  • Wilkie, Dean
  • Petrenciuc, Oana
  • Chen, Eric X

publication date

  • August 20, 2007

has subject area